| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bc5292a07e34d16eb1d033a16d3aec3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2014-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5c46e00ea1cced62f38f56a3e9f1336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7b21f276e38e6f430980d6d384c21b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed1123280cee798d557f48bb217a6e3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96b450f69400f417fe0b455d61e99991 |
| publicationDate |
2014-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014165701-A1 |
| titleOfInvention |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| abstract |
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT 6) receptor antagonists are provided for improving the cognition of a Down syndrome patient. Through the use of a mouse model of DS, the Ts65Dn mouse, we disclose evidence herein that 5-HT 6 receptor antagonists may alleviate the cognitive deficits observed in human subjects suffering from DS. Species within the claimed genus of 5-HT6 receptor antagonists restored the cognitive function of Ts65Dn mice almost to the level of control mice as demonstrated by an improved ability to differentiate between a familiar object in a familiar location and a novel object in a novel location. Consequently, the data disclosed herein support the claimed use of 5-HT 6 receptor antagonists for the treatment of cognitive deficits associated with DS. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7167065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018215478-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110667435-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11464759-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2776366-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020520964-A |
| priorityDate |
2013-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |